PT-141 / Bremelanotide

PT-141 (Bremelanotide) is a synthetic peptide analog of alpha-melanocyte stimulating hormone (α-MSH). It acts as a non-selective agonist at melanocortin receptors 1, 3, 4, and 5. Approved by the FDA in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, it is the first drug approved for this indication that works on the central nervous system rather than peripheral blood flow.

PubMed results: 87 · Human studies: 62 · Animal studies: 67

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

FDA-approved dosing

• Subcutaneous Injection — standard range 1.75 mg, As needed before anticipated sexual activity. Maximum 1 dose per 24 hours, maximum 8 doses per month

2.7 hours (high confidence)

• Improved sexual desire (Strong human clinical data): RECONNECT trials demonstrated significant improvements in sexual desire and distress

• Nausea — Moderate, Common (40%)
• Flushing — Mild, Common (20%)

• NCT00425256 — Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD) (PHASE2), status: COMPLETED. Indications: Sexual Arousal Disorder
• NCT02338960 — 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (PHASE3), status: COMPLETED. Indications: Hypoactive Sexual Desire Disorder
• NCT02333071 — 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (PHASE3), status: COMPLETED. Indications: Hypoactive Sexual Desire Disorder
• NCT01382719 — Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder (PHASE2), status: COMPLETED. Indications: Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder